Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600–Mutant Solid Tumors ASCO Guidelines provide ...
At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
Graig Suvannavejh, Managing Director of Equity Research at Mizuho Securities, discusses major ASCO presentations, biotech volatility, cancer breakthroughs and emerging oncology companies to watch. Got ...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...
Pharma brands are increasingly investing in having a big brand presence at ASCO, with marketers and sales reps manning booths, hoping to carve out a place in a highly competitive oncology arena.
Carvykti inventor Frank Fan hopes his new CAR-T venture, Wondercel Therapeutics, may replicate the commercial partnership model that Legend Biotech has with J&J. (Frank Fan) Nine years after wowing ...
RASolute 302 showed daraxonrasib reduced mortality risk by 60% versus chemotherapy in previously treated metastatic PDAC, with median OS 13.2 versus 6.7 months. OPTIMA found Prosigna-defined low-risk ...
Above the scientific discussions and deal talks at ASCO 2026, the dark cloud of geopolitics hovered over the Chicago convention center. (Angus Liu/Fierce Pharma) In 2017, a little-known company called ...
Lilly's upcoming label expansion proposal for 2020-approved Retevmo is "in many ways, the final chapter of the development program" for the drug, oncology head Jacob Van Naarden said in an interview. ...
Tempus AI (TEM) stock immediately jumped over ~3% to ~$53.15 before pulling back on Friday after unveiling new AI-driven precision medicine data at the 2026 ASCO Annual Meeting. The healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results